Anthony B. Evnin, Director at Juno Therapeutics, Inc. (JUNO), bought 9,000 shares at $24.40 ($220K) on 2017-06-20, disclosed to the SEC on 2017-06-21.
Open-market purchase of $220k JUNO by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| Filing → |
| CNST | BUY | 2019-10-04 | $48.0M | — | Filing → |
| AVEO | BUY | 2018-11-26 | $223 | — | Filing → |
| AVEO | SELL | 2018-11-16 | $4.3M | — | Filing → |